Inovio Pharmaceuticals, Inc. (INO)

NASDAQ: INO · Real-Time Price · USD

1.320

+0.030 (2.33%)

Aug 26, 2026, 2:13 PM EDT - Market open

Inovio Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	31.53	44.27	65.81	14.31	46.33	71.14
Short-Term Investments	5.15	14.24	28.3	130.98	206.67	330.17
Cash & Short-Term Investments	36.67	58.51	94.11	145.29	253	401.31
Cash Growth	-22.87%	-37.83%	-35.23%	-42.57%	-36.96%	-2.51%
Receivables	-	0	1.2	2.41	11.74	8.03
Prepaid Expenses	3.24	2.61	2.52	5.41	20.51	39.1
Other Current Assets	-	-	-	-	30	-
Total Current Assets	39.91	61.12	97.83	153.11	315.24	448.44
Property, Plant & Equipment	7.56	9.07	11.77	14.45	17.96	29.02
Long-Term Investments	-	2.1	1.61	2.78	2.01	3.91
Goodwill	-	-	-	-	10.51	10.51
Other Intangible Assets	-	-	-	-	2.13	2.63
Other Long-Term Assets	1.92	2.01	1.98	0.61	0.68	1.43
Total Assets	49.39	74.31	113.2	170.95	348.53	495.94

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	3.64	2.62	6.44	4.65	21.08	27.97
Accrued Expenses	8.35	9.16	13.13	18.64	26.42	30.55
Current Portion of Long-Term Debt	-	-	-	16.77	-	-
Current Portion of Leases	2.9	2.82	2.5	2.41	2.8	2.6
Current Unearned Revenue	-	-	-	0.11	2.56	4.62
Other Current Liabilities	25.02	29.07	13.26	-	44	-
Total Current Liabilities	39.92	43.67	35.33	42.57	96.87	65.74
Long-Term Debt	-	-	-	-	16.61	14.96
Long-Term Leases	5.1	6.55	9.37	11.03	12.66	15.46
Long-Term Unearned Revenue	-	-	-	-	-	0.06
Long-Term Deferred Tax Liabilities	-	-	-	-	0.03	0.03
Other Long-Term Liabilities	-	-	-	-	-	0.01
Total Liabilities	45.02	50.21	44.69	53.6	126.17	96.27

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.08	0.07	0.04	0.02	0.02	0.22
Additional Paid-In Capital	1,845	1,840	1,799	1,741	1,711	1,610
Retained Earnings	-1,841	-1,815	-1,730	-1,623	-1,488	-1,210
Comprehensive Income & Other	-0.28	-0.64	-0.68	-0.66	-0.7	-0.28
Total Common Equity	4.37	24.1	68.5	117.35	222.36	399.67
Shareholders' Equity	4.37	24.1	68.5	117.35	222.36	399.67
Total Liabilities & Equity	49.39	74.31	113.2	170.95	348.53	495.94

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	8	9.37	11.87	30.21	32.07	33.02
Net Cash (Debt)	28.67	49.14	82.25	115.08	220.92	368.29
Net Cash Growth	-22.28%	-40.25%	-28.53%	-47.91%	-40.01%	-1.16%
Net Cash Per Share	0.44	1.05	3.03	5.19	11.11	21.16
Filing Date Shares Outstanding	103.4	69.09	36.67	23.37	21.68	18.12
Total Common Shares Outstanding	82.34	69	36.1	22.79	21.09	18.12
Working Capital	-0	17.45	62.5	110.54	218.37	382.7
Book Value Per Share	0.05	0.35	1.90	5.15	10.54	22.06
Tangible Book Value	4.37	24.1	68.5	117.35	209.72	386.53
Tangible Book Value Per Share	0.05	0.35	1.90	5.15	9.94	21.34
Machinery	-	8.13	8.36	9.9	13.49	20.59
Leasehold Improvements	-	11.82	11.76	15.92	15.8	15.8

SEC Filings: 10-K · 10-Q